MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it has completed patient enrollment in the pivotal registration Phase 3 clinical trial designed to evaluate the safety and efficacy of Gabapentin GR™ for the treatment of postherpetic neuralgia (PHN). The company expects to announce results from this trial mid-year.
